Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 225

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 225
---
 Ordinary Shares
in an amount that is approximately proportionate to that underwriter’s initial purchase commitment (set forth in the table above).
Any shares of our Ordinary Shares issued or sold under the option will be issued and sold on the same terms and conditions as the other
shares of our Ordinary Shares that are the subject of this offering. If this option is exercised in full, the total offering price to
the public will be $ million and the total net proceeds to us, before expenses, will be $ million.

<div align='center'>136</div>

Discounts and Commissions

The underwriters have advised
that the underwriters propose to offer the Ordinary Shares to the public at the public offering price per share set forth on the cover
page of this prospectus. The underwriters may offer the Ordinary Shares to securities dealers at that price less a concession of not more
than $ per share, of which up to may be re-allowed to other dealers.

The following table summarizes
the public offering price, underwriting discounts and commissions, and proceeds to us before expenses, assuming both no exercise and full
exercise by the Representative of the over-allotment option.

|                                  |     | Per Share |     | Total     
 Without   
 Over-     
 Allotment |     | With      
 Over-     
 Allotment |
|:---------------------------------|:----|:----------|:----|:----------|:----|:----------|
| Public offering price            |     | $         |     |           |     |           |
| Underwriting discount (7.0%)(1)  |     | $         |     |           |     |           |
| Proceeds, before expenses, to us |     | $         |     |           |     |           |

| (1) | We have agreed to pay a non-accountable expense allowance to the Representative equal to 1.0% of the gross proceeds received in this offering (excluding proceeds received from exercise of the Representative’s over-allotment option) which is not included in the underwriting discounts and commission. |

We have paid an expense deposit
of $35,000 to the Representative, which will be applied against the Representative’s actual out-of-pocket accountable expenses that
are payable by us in connection with this offering and such expense deposit shall be reimbursed to the Company to the extent any portion
thereof is not actually incurred in compliance with FINRA Rule 5110(g)(4)(A). We have agreed to reimburse the Representative for the